1 INTRODUCTION OF GLOBAL ANATOMIC PATHOLOGY MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
4 GLOBAL ANATOMIC PATHOLOGY MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS
5 GLOBAL ANATOMIC PATHOLOGY MARKET, BY PRODUCT AND SERVICES
5.1 OVERVIEW
5.2 SERVICES
5.2.1 HISTOPATHOLOGY
5.2.2 CYTOPATHOLOGY
5.3 INSTRUMENTS
5.3.1 SLIDE STAINING SYSTEMS
5.3.2 TISSUE PROCESSING SYSTEMS
5.3.3 CELL PROCESSORS
5.3.4 MICROTOMES
5.3.5 EMBEDDED SYSTEMS
5.3.6 COVERSLIPPERS
5.3.7 OTHERS
5.4 CONSUMABLES
5.4.1 ANTIBODIES
5.4.1.1 PRIMARY ANTIBODIES
5.4.1.2 SECONDARY ANTIBODIES
5.4.2 KITS & REAGENTS
5.4.2.1 STAINS & SOLVENTS
5.4.2.2 FIXATIVES
5.4.2.3 OTHERS
5.5 PROBES
5.6 OTHER CONSUMABLES
6 GLOBAL ANATOMIC PATHOLOGY MARKET, BY APPLICATION
6.1 OVERVIEW
6.2 DISEASE DIAGNOSIS
6.3 CANCER
6.3.1 BREAST CANCER
6.3.2 LUNG CANCER
6.3.3 GASTROINTESTINAL CANCER
6.3.4 PROSTATE CANCER
6.3.5 OTHERS
6.4 MEDICAL RESEARCH
7 GLOBAL ANATOMIC PATHOLOGY MARKET, BY END-USER
7.1 OVERVIEW
7.2 HOSPITAL LABORATORIES
7.3 CLINICAL LABORATORIES
7.4 OTHER END USERS

8 GLOBAL ANATOMIC PATHOLOGY MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3. 1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE

8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL ANATOMIC PATHOLOGY MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
10 COMPANY PROFILES
10.1 AGILENT TECHNOLOGIES, INC.
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.2 BIO SB
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.3 BIOGENEX
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.4 CARDINAL HEALTH
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.5 DANAHER CORPORATION
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.6 F. HOFFMANN-LA ROCHE AG
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.7 LABORATORY CORPORATION OF AMERICA HOLDINGS
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.8. NEOGENOMICS LABORATORIES, INC.
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.9 PHC HOLDINGS CORPORATION
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.10 QUEST DIAGNOSTICS INCORPORATED
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.11 SAKURA FINETEK USA, INC.
10.11.1 OVERVIEW
10.11.2 FINANCIAL PERFORMANCE
10.11.3 PRODUCT OUTLOOK
10.11.4 KEY DEVELOPMENTS